Practice Essentials

Going Beyond the Cookie-Cutter Approach: Individualizing Therapeutic Decisions in CML
Going Beyond the Cookie-Cutter Approach: Individualizing Therapeutic Decisions in CML
CME, CPE, CNE
Stuart L. Goldberg, MD; Harry P. Erba, MD, PhD
Release Date: July 07, 2015
Expiration Date: July 07, 2016
Dr. Stuart Goldberg and Dr. Harry Erba discuss how to individualize therapeutic decisions for your patients with CML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis and Teva Pharmaceuticals
View Only, CE ExpiredView Only, No Credit
 
TKI Treatment Failure: What You Need to Know
TKI Treatment Failure: What You Need to Know
CME, CPE
Stuart L. Goldberg, MD; Karen P. Seiter, MD
Release Date: April 02, 2015
Expiration Date: April 02, 2016

Join our Managing CML team experts, Stuart Goldberg, MD, Division of Leukemia at the John Theurer Cancer Center in Hackensack, New Jersey, and Karen Seiter, MD, professor of medicine at New York Medical College, Division of Oncology/Hematology in Valhalla, New York, as they share their personal practice experiences of patients who have developed primary and secondary treatment resistance. Their discussion, centered around actual case encounters in their practice, provides health care professionals that treat and care for chronic myeloid leukemia patients with what they need to know about both primary and secondary treatment resistance, including how to rapidly assess the causes of failure and implement strategies to overcome them.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis and Teva Pharmaceuticals
View Only, CE ExpiredView Only, No Credit
 
Newly Diagnosed Chronic Myeloid Leukemia: Essentials in Treatment and Monitoring
Newly Diagnosed Chronic Myeloid Leukemia: Essentials in Treatment and Monitoring
CME, CPE, CNE
Stuart L. Goldberg, MD
Release Date: September 06, 2013
Expiration Date: September 06, 2014
Dr. Goldberg discusses newly diagnosed chronic myeloid leukemia (CML) and what is essential to know for the treatment and monitoring of this disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Teva Pharmaceuticals and Novartis Corporation.
View Only, CE ExpiredView Only, No Credit
 
Newly Diagnosed CML: Addressing Secondary Resistance
Newly Diagnosed CML: Addressing Secondary Resistance
CME, CPE, CNE
Jerald P. Radich, MD
Release Date: August 02, 2013
Expiration Date: August 02, 2014
Dr. Radich discusses newly diagnosed chronic myeloid leukemia (CML) and how to address secondary resistance to primary therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Teva Pharmaceuticals and Novartis Corporation.
View Only, CE ExpiredView Only, No Credit
 
New Paradigms in Chronic Myelogenous Leukemia
New Paradigms in Chronic Myelogenous Leukemia
Eric J. Feldman, MD; Neil Shah, MD, PhD
Release Date: February 20, 2013
Expiration Date: February 20, 2014
Join Dr. Feldman and Dr. Shah for a joint conversation regarding specific management considerations in a series of real-world CML cases.

In a supplemental resource (not required for credit), Dr. Feldman leads a discussion regarding treatment and management options for chronic myelogenous leukemia (CML), including trial outcomes for emerging therapeutic approaches.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.
View Only, CE ExpiredView Only, No Credit